$1.23
3.91% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US44148G1058
Symbol
HOTH

Hoth Therapeutics, Inc. Stock price

$1.23
-0.30 19.61% 1M
+0.33 37.35% 6M
+0.48 64.42% YTD
+0.33 37.12% 1Y
-3.18 72.11% 3Y
-43.27 97.24% 5Y
-212.02 99.42% 10Y
-212.02 99.42% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
-0.05 3.91%
ISIN
US44148G1058
Symbol
HOTH
Industry

Key metrics

Basic
Market capitalization
$16.3m
Enterprise Value
$7.3m
Net debt
positive
Cash
$9.0m
Shares outstanding
13.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
89.2%
Return on Equity
-119.0%
ROCE
-104.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-10.2m | $-12.0m
Net Income
$-10.2m | $-7.0m
Free Cash Flow
$-8.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-36.0% | -45.8%
Net Income
-36.6% | 14.3%
Free Cash Flow
-9.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
3.1%
Employees
3
Rev per Employee
$0.0
Show more

Is Hoth Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Hoth Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Hoth Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Hoth Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.97 4.97
1% 1%
-
- Research and Development Expense 5.22 5.22
63% 63%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -10 -10
36% 36%
-
Net Profit -10 -10
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hoth Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hoth Therapeutics, Inc. Stock News

Neutral
PRNewsWire
12 days ago
Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U...
Neutral
PRNewsWire
18 days ago
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): Complete GLP toxicology and CMC packages; submit IND.
Neutral
PRNewsWire
about one month ago
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on devel...
More Hoth Therapeutics, Inc. News

Company Profile

Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.

Head office United States
CEO Robbie Knie
Employees 3
Founded 2017
Website hoththerapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today